Result of Retail Offer

Further to the announcement dated 16 November 2023, SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, is pleased to announce that, following the closing of the Retail Offer on the BookBuild platform on 20 November 2023, 1,315,789 Ordinary Shares will be issued at the Issue Price of 19 pence per Retail Offer Share in connection with the Retail Offer, raising an additional £0.25 million.

As the Retail Offer was heavily oversubscribed, allocation was made to existing Shareholders applying the principles of soft pre-emption. Shareholders were allocated 100% of their soft pre-emptive allowance. Where the order was greater than the soft pre-emptive allowance shareholders received c.37% of their additional demand. (1)

Consequently, 15,908,298 Placing Shares and 1,315,789 Retail Offer Shares, resulting in a total of 17,224,087 new Ordinary Shares, will be issued in relation to the Placing and Retail Offer, raising total gross proceeds of £3.3 million.

Application has been made for the Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on or around 22 November 2023.

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 190,362,941 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 190,362,941. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

• Soft Pre-emptive allowance Calculation: shareholder existing shares X 9.048% (Dilution from total new shares being issued) = Soft Pre-emptive allowance allocation shares

Additional Demand: (Total Order shares - Soft Pre-emptive allowance allocation shares) x c.37.033% = Additional demand allocation shares

UK Product Governance Requirements

EU Product Governance Requirements